As a result, we do not foresee that p16 immunohistochemistry is an effective screening tool for CDKN2A inactivation in CNS WHO grade 1 meningiomas and only recommend p16 immunohistochemical evaluation in higher grade meningiomas. This evidence concerns the gene CDKN2A and meningioma.